Genzyme to supply less than half of EU demand for Thyrogen
This article was originally published in Scrip
Executive Summary
For the next several months, Genzyme will only be able to meet around 45% of the demand for its Thyrogen (thyrotropin alfa) in the EU, the company has warned the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP). The problem should be resolved by July when logistical issues connected with the transfer of manufacturing should be resolved.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.